Pfizer (PFE) Bullish Stance Reiterated at Jefferies

Jefferies analyst Jeffrey Holford, PhD reiterated a Buy rating and $36 price target on Pfizer (NYSE: PFE) following meetings with management.

Holford commented, "We remain highly convinced that palbo will get approved before year-end 2014 and dominate the ER+/ HER2- breast cancer category as well as generate significant new growth opportunities. We were also encouraged by Pfizer's increasing commitment toward developing an Immuno-Oncology platform both internally as well as in collaboration with other players. PFE remains our Top Pick in Global Large Cap Pharmaceuticals."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $29.60 yesterday.

You May Also Be Interested In

• Pfizer Declares Second-Quarter 2024 Dividend
• Comcast Corp (CMCSA) PT Lowered to $48 at Pivotal Research
• MarineMax (HZO) PT Lowered to $35 at Stifel